{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:04Z","timestamp":1791996424525,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07178-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:34:51Z","timestamp":1784273691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Romejko-Jarosi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Majcherek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szeremet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Kwa\u015bnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"7178_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","volume":"36","author":"N Monga","year":"2020","unstructured":"Monga N, Garside J, Quigley J et al (2020) Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin 36:843\u2013852","journal-title":"Curr Med Res Opin"},{"issue":"suppl4","key":"7178_CR2","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O et al (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl4):iv62\u2013iv71","journal-title":"Ann Oncol"},{"key":"7178_CR3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E et al (2024) Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403:2293\u20132306","journal-title":"Lancet"},{"key":"7178_CR4","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","volume":"6","author":"M Narkhede","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L et al (2022) Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 6:4122\u20134131","journal-title":"Blood Adv"},{"key":"7178_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M et al (2016) 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 175:410\u2013418","journal-title":"Br J Haematol"},{"key":"7178_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"7178_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL et al (2018) Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391:659\u2013667","journal-title":"Lancet"},{"key":"7178_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331\u20131342","journal-title":"N Engl J Med"},{"key":"7178_CR9","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/cncr.29498","volume":"121","author":"JE Vaughn","year":"2015","unstructured":"Vaughn JE, Sorror ML, Storer BE et al (2015) Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer 121:3709\u20133716","journal-title":"Cancer"},{"key":"7178_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H et al (2018) Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: A retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transpl 53:617\u2013624","journal-title":"Bone Marrow Transpl"},{"key":"7178_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/10428194.2018.1468894","volume":"60","author":"JD Sandoval-Sus","year":"2019","unstructured":"Sandoval-Sus JD, Faramand R, Chavez J et al (2019) Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: Results from a single institution study. Leuk Lymphoma 60:309\u2013316","journal-title":"Leuk Lymphoma"},{"key":"7178_CR12","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cancers14112673","volume":"14","author":"A Gutierrez","year":"2022","unstructured":"Gutierrez A, Bento L, Novelli S et al (2022) Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH\/GELTAMO Experience. Cancers (Basel) 14:2673","journal-title":"Cancers (Basel)"},{"key":"7178_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1080\/13696998.2024.2422227","volume":"27","author":"L Cai","year":"2024","unstructured":"Cai L, Roos J, Miranda PAP et al (2024) Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed\/refractory mantle cell lymphoma. J Med Econ 27:1552\u20131557","journal-title":"J Med Econ"},{"key":"7178_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496","journal-title":"Blood"},{"key":"7178_CR15","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333\u20131338","journal-title":"Blood"},{"key":"7178_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695\u2013706","journal-title":"Stat Med"},{"key":"7178_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN et al (2020) Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl 26:1247\u20131256","journal-title":"Biol Blood Marrow Transpl"},{"key":"7178_CR18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S et al (1994) ESHAP \u2014 an effective chemo-therapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169\u20131176","journal-title":"J Clin Oncol"},{"key":"7178_CR19","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/JCO.1995.13.7.1734","volume":"13","author":"MA Rodriguez","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Velasquez W et al (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734\u20131741","journal-title":"J Clin Oncol"},{"key":"7178_CR20","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/cncr.23880","volume":"113","author":"M Wang","year":"2008","unstructured":"Wang M, Fayad L, Cabanillas F et al (2008) Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113:2734\u20132741","journal-title":"Cancer"},{"key":"7178_CR21","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822\u20133829","journal-title":"J Clin Oncol"},{"key":"7178_CR22","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867\u20134874","journal-title":"J Clin Oncol"},{"key":"7178_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3324\/haematol.2022.282469","volume":"109","author":"S Le Gouill","year":"2024","unstructured":"Le Gouill S, D\u0142ugosz-Danecka M, Rule S et al (2024) Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 109:343\u2013350","journal-title":"Haematologica"},{"key":"7178_CR24","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M et al (2024) Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 11:e147\u2013e159","journal-title":"Lancet Haematol"},{"key":"7178_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2019","unstructured":"Dreger P, Michallet M, Bosman P et al (2019) Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transpl 54:44\u201352","journal-title":"Bone Marrow Transpl"},{"key":"7178_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A et al (2023) Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 41:555\u2013567","journal-title":"J Clin Oncol"},{"key":"7178_CR27","doi-asserted-by":"crossref","unstructured":"Baermann B-N, Dietrich S (2024) Mantle Cell Lymphoma. In: Sureda A, Corbacioglu S, Greco R, Kroger N, Carreras E (eds) The EBMT Handbook. Springer, pp 787\u2013790","DOI":"10.1007\/978-3-031-44080-9_87"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07178-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:04:56Z","timestamp":1791993896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7178"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07178-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Trial registration number: clinicaltrials.gov: NCT04716075, trial registration date 17.12.2020.","order":1,"name":"Ethics","label":"Clinical trial","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SG: Astra Zeneca \u2013 honoraria, advisory boards, research grant; Abbvie - honoraria, speakers bureau, advisory boardsAC: Abbvie - honoraria; Takeda \u2013 honoraria, advisory boards IH: Abbvie, Astra Zeneca, Beigene, Janssen, Lilly, Roche \u2013 honoraria, speakers bureau, advisory boardsWJ: Astra Zeneca \u2013 honoraria, advisory board, research grant; Abbvie, Janssen, Lilly, Roche, Takeda \u2013 honoraria, advisory boards.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"454"}}